Selective suppression of neutrophil accumulation in ongoing pulmonary inflammation by systemic inhibition of p38 mitogen-activated protein kinase

Journal of Immunology

Volumn 169, Issue 9, 2002, Pages 5260-5269

  Nick, Jerry A ^a   Young, Scott K ^a   Arndt, Patrick G ^a   Lieber, Jonathan G ^a   Suratt, Benjamin T ^a   Poch, Katie R ^a   Avdi, Natalie J ^a   Malcolm, Ken C ^a   Taube, Christian ^a   Henson, Peter M ^a   Worthen, G Scott ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; LUNG LAVAGE; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN SECRETION; SERUM;

EID: 0036838563     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.9.5260     Document Type: Article

References (77)

1. Worthen, G. S., B. Schwab, E. L. Elson, and G. P. Downey. 1989. Mechanics of stimulated neutrophils: Cell stiffening induces retention in capillaries. Science 245:183.
2. Downey, G. P., D. E. Doherty, B. Schwab III, E. L. Elson, P. M. Henson, and G. S. Worthen. 1990. Retention of leukocytes in capillaries: Role of cell size and deformability. J. Appl. Physiol. 69:1767.
3. Lien, D. C., W. W. Wagner, R. L. Capen, C. L. Haslett, W. L. Hanson, S. E. Hofmeister, P. M. Henson, and G. S. Worthen. 1987. Physiologic neutrophil sequestration in the canine pulmonary circulation: Evidence for localization in capillaries. J. Appl. Physiol. 62:1236.
4. Worthen, G. S., and J. A. Nick. 1998. Leukocyte accumulation in the lung. In Pulmonary Diseases and Disorders, Vol. 1. A. P. Fishman, ed. McGraw-Hill, New York, p. 325.
5. Xing, Z., H. Kirpalani, D. Torry, M. Jordana, and J. Gauldie. 1993. Polymorphonuclear leukocytes as a significant source of TNF-A in endotoxin-challenged lung tissue. Am. J. Pathol. 143:1009.
6. Doherty, D. E., G. P. Downey, B. I. Schwab, E. Elson, and G. S. Worthen. 1994. Lipopolysaccharide-induced monocyte retention in the lung: Role of monocyte stiffness, actin assembly, and CD18-dependent adherence. J. Immunol. 153:241.
7. Cobb, M. H., and E. J. Goldsmith. 1995. How MAP kinases are regulated. J. Biol. Chem. 270:14843.
8. Han, J., J.-D. Lee, L. Bibbs, and R. J. Ulevitch. 1994. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265:808.
9. Rouse, J., P. Cohen, S. Trigon, M. Morange, A. Alonso-Llamazares, D. Zamanillo, T. Hunt, and A. R. Nebreda. 1994. A novel kinase cascade triggered by chemical stress and heat shock which stimulates MAP kinase-activated protein kinase-2 and phosphorylation of the small heat shock proteins. Cell 78:1027.
10. Lee, J. C., J. T. Laydon, P. C. McDonnell, T. F. Gallagher, S. Kumar, D. Green, D. McNulty, M. J. Blumenthal, J. R. Heys, S. W. Landvatter, et al. 1994. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739.
11. Manthey, C. L., S.-W. Wang, S. D. Kinney, and Z. Yao. 1998. SB202190, a selective inhibitor of p38 mitogen-activated protein kinase, is a powerful regulator of LPS-induced mRNAs in monocytes. J. Leukocyte Biol. 64:409.
12. Nick, J. A., S. K. Young, K. Brown, N. J. Avdi, P. G. Arndt, B. T. Suratt, M. S. Janes, P. M. Henson, and G. S. Worthen. 2000. Role of p38 MAP kinase in a murine model of pulmonary inflammation. J. Immunol. 164:2151.
13. Matsumato, K., S. Hashimoto, Y. Gon, T. Nakayama, and T. Horie. 1998. Proinflammatory cytokine-induced and chemical mediator-induced IL-8 expression in human bronchial epithelial cells through p38 mitogen-activated protein kinase-dependent pathway. J. Allergy Clin. Immunol. 101:825.
14. Schumann, R. R., D. Pfeil, N. Lamping, C. Kirschning, G. Scherzinger, P. Schlag, L. Karawajew, and F. Herrmann. 1996. LPS induces the rapid tyrosine phosphorylation of the MAP kinases erk-1 and p38 in cultured human vascular endothelial cells requiring the presence of soluble CD14. Blood 87:2805.
15. Nick, J. A., N. J. Avdi, S. K. Young, C. Knall, G. L. Johnson, and G. S. Worthen. 1997. Common and distinct intracellular signalling pathways in human neutrophil utilized by platelet activating factor and FMLP. J. Clin. Invest. 99:975.
16. Zu, Y.-L., J. Qi, A. Gilchrist, G. A. Fernandez, D. Vazquez-Abad, D. L. Kreutzer, C.-K. Huang, and R. I. Sha'afi. 1998. p38 mitogen-activated protein kinase activation is required for human neutrophil function triggered by TNF-α or FMLP stimulation. J. Immunol. 160:1982.
17. 2-integrin-dependent neutrophil adhesion and the adhesion-dependent oxidative burst. J. Immunol. 161:1921.
18. Frasch, S. C., J. A. Nick, V. A. Fadok, D. L. Bratton, G. S. Worthen, and P. M. Henson. 1998. p38 mitogen-activated protein kinase-dependent and -independent intracellular signal transduction pathways leading to apoptosis in human neutrophils. J. Biol. Chem. 273:8389.
19. Weinstein, S. L., J. S. Sanghera, K. Lemke, A. L. DeFranco, and S. L. Pelech. 1992. Bacterial lipopolysaccharide induces tyrosine phosphorylation and activation of mitogen-activated protein kinases in macrophages. J. Biol. Chem. 267:14955.
20. Swantek, J. L., M. H. Cobb, and T. D. Geppert. 1997. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor α (TNF-α) translation: Glucocorticoids inhibit TNF-α translation by blocking JNK/SAPK. Mol. Cell. Biol. 17:6274.
21. Hambleton, J., S. L. Weinstein, L. Lem, and A. L. DeFranco. 1996. Activation of c-Jun N-terminal kinase in bacterial LPS-stimulated macrophages. Proc. Natl. Acad. Sci. USA 93:2774.
22. 2 production in LPS-stimulated monocytes. J. Immunol. 161:5681.
23. Lu, H.-T., D. D. Young, M. Wysk, E. Gatti, I. Mellman, R. J. Davis, and R. A. Flavell. 1999. Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice. EMBO J. 18:1845.
24. Schafer, P. H., L. Wang, S. A. Wadsworth, J. E. Davis, and J. J. Siekierka. 1999. T cell activation signals up-regulate p38 mitogen-activated protein kinase activity and induce TNF-α production in a manner distinct from LPS activation of monocytes. J. Immunol. 162:659.
25. Nick, J. A., N. J. Avdi, P. Gerwins, G. L. Johnson, and G. S. Worthen. 1996. Activation of a p38 mitogen-activated protein kinase in human neutrophils by lipopolysaccharide. J. Immunol. 156:4867.
26. Nahas, N., T. F. P. Molski, G. A. Fernandez, and R. I. Sha'afi. 1996. Tyrosine phosphorylation and activation of a new mitogen-activated protein (MAP)-kinase cascade in human neutrophil stimulated with various agonists. Biochem. J. 318:247.
27. Fouda, B. I., T. F. P. Molski, M. S. Ashour, and R. I. Sha'afi. 1995. Effect of lipopolysaccharide on mitogen-activated protein kinases and cytosolic phospholipase A2, Biochem. J. 308:815.
28. Liverton, N. J., J. W. Butcher, C. F. Claiborne, D. A. Claremon, B. E. Libby, K. T. Nguyen, S. M. Pitzenberger, H. G. Selnick, G. R. Smith, A. Tebben, et al. 1999. The design and synthesis of potent, selective and orally bioavailable tetrasubstituted imidazole inhibitors of p38 MAP kinase. J. Med. Chemistry 42:2180.
29. Manthey, C. L., and S. N. Vogel. 1994. Elimination of trace endotoxin protein from rough chemotype LPS. J. Endotoxin Res. 1:84.
30. Hirschfeld, M., Y. Ma, J. H. Weis, S. N. Vogel, and J. J. Weis. 2000. Repurification of LPS eliminates signaling through both human and murine Toll-like receptor 2. J. Immunol. 165:618.
31. Haslett, C., L. A. Guthrie, M. Kopaniak, R. B. Johnston, Jr., and P. M. Henson. 1985. Modulation of multiple neutrophil functions by trace amounts of bacterial LPS and by preparative methods. Am. J. Pathol. 119:101.
32. Gruler. H., and B. D. Bultmann. 1984. Analysis of cell movement. Blood Cells 10:61.
33. Cassatella, M. 1995. The production of cytokines by polymorphonuclear neutrophils. Immunol, Today 16:21.
34. Cara, D. C., J. Kaur, M. Forster, D. M. McCafferty, and P. Kubes. 2001. Role of p38 MAPK in chemokine-induced emigration and chemotaxis in vivo. J. Immunol. 167:6552.
35. Goebeler, M., K. Kilian, R. Gillitzer, M. Kunz, T. Yoshimura, E. B. Brocker, U. R. Rapp, and S. Ludwig. 1999. The MKK6/p38 stress kinase cascade is critical for TNF-induced expression of MCP-1 in endothelial cells. Blood 93:857.
36. Nakano, Y., T. Kasahara, N. Mukaida, Y. C. Ko, M. Nakano, and K. Matsushima. 1994. Protection against lethal bacterial infection in mice by monocyte-chemotactic and -activating factor. Infect. Immun. 62:377.
37. Griswold, D. E., S. Hoffstein, P. J. Marshall, E. F. Webb, L. Hillegass, P. E. Bender, and N. Hanna. 1989. Inhibition of inflammatory cell infiltration by bicyclic imidazoles, SK&F 86002 and SK&F 104493. Inflammation 13:727.
38. Griswold, D. E., L. M. Hillegass, P. C. Meunier, M. J. DiMartino, and N. Hanna. 1988. Effect of inhibitors of eicosanoid metabolism in murine collagen-induced arthritis. Arthritis Rheum. 31:1406.
39. Badger, A. M., J. N. Bradbeer, B. Votta, J. C. Lee, J. L. Adams, and D. E. Griswold. 1996. Pharmacologic profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Ther. 279:1453.
40. Lee, J. C., A. M. Badger, D. E. Griswold, D. Dunnington, A. Truneh, B. Votta, J. R. White, P. R. Young, and P. E. Bender. 1993. Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors. Ann. NY Acad. Sci. 696:149.
41. Underwood, D. C., R. R. Osborn, C. J. Kotzer, J. L. Adams, J. C. Lee, E. F. Webb, D. C. Carpenter, S. Bochnowicz, H. C. Thomas, D. W. P. Hay, and D. E. Griswold. 2000. SB 239063, a potent p38 MAPK inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J. Pharmacol. Exp. Ther. 293:281.
42. Reddy, M. P., E. F. Webb, D. Cassatt, D. Maley, J. C. Lee, D. E. Griswold, and A. Truneh. 1994. Pyridinyl imidazoles inhibit the inflammatory phase of delayed type hypersensitivity reactions without affecting T-dependent immune responses. Int. J Immunopharmacol. 16:795.
43. Jackson, J. R., B. Bolognese, L. Hillegass, S. Kassis, J. Adams, D. E. Griswold, and J. D. Winkler. 1998. Pharmacological effects of SB 220025, a selective inhibitor of p38 MAPK, in angiogenesis and chronic inflammatory disease models. J. Pharmacol. Exp. Ther. 284:687.
44. Bradbeer, J. N., R. D. Kapadia, S. K. Sarkar, H. Zhao, G. B. Stroup, B. A. Swift, D. J. Rieman, and A. M. Badger. 1996. Disease-modifying activity of SK&F106615 in rat adjuvant-induced arthritis. Arthritis Rheum. 39:504.
45. Olivera, D. L., J. T. Laydon, L. Hillegass, A. M. Badger, and J. C. Lee. 1993, Effects of pyridinyl imidazole compounds on murine TNF-α production. Agents Actions 39:C55.
46. Escott, K. J., M. G. Belvisi, M. A. Birrell, S. E. Webber, M. L. Foster,. and C. A. Sargent. 2000. Effect of the p38 kinase inhibitor, SB 203580, on allergic airway inflammation in the rat. Br. J. Pharmacol. 131-173.
47. Blink, B. V. d., N. P. Juffermans, T. T. Hove, M. J. Schultz, S. J. H. V. Deventer, T. V. D. Poll, and M. P. Peppelenbosch. 2001. p38 MAPK inhibition increases cytokine release in vitro and during infection in vivo. J. Immunol. 166:582.
48. Birrell, M., D. Hele, K. McCluskie, S. Webber, M. Foster, and M. G. Belvisi. 2000. Effect of the p38 kinase inhibitor, SB 203580, on sephadex induced airway inflammation in the rat. Eur. Respir. J. 16:947.
49. Underwood, D. C., R. R. Osbom, S. Bochnowicz, E. F. Webb, D. J. Reiman, J. C. Lee, A. M. Romanic, J. L. Adams, D. W. P. Hay, and D. E. Griswold. 2000. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am. J. Physiol. 279.L895.
50. Yoshinari, D., I. Takeyoshi, Y. Koibuchi, K. Matsumoto, Y. Kawashima, T. Koyama, S. Ohwada, and Y. Morishita. 2001. Effect of a duel inhibitor of TNF-α and IL-1 on LPS-induced lung injury in rats: Involvement of the p38 MAPK pathway. Crit. Care Med. 29:628.
51. Denham, W., J. Yang, H. Wang, G. Botchkina, K. J. Tracey, and J. Norman. 2000. Inhibition of p38 MAPK attenuates the severity of pancreatitis-induced ARDS. Crit. Care Med. 28:2567.
52. Yang, J., C. Murphy, W. Denham, G. Botchkina, K. J. Tracey, and J. Norman. 1999. Evidence of a central role for p38 MAPK induction of TNF-α in pancreatitis-associated pulmonary injury. Surgery 126:216.
53. Kawashima, Y., I. Takeyoshi, Y. Otani, Y. Koibuchi, D. Yoshinari, T. Koyama, M. Kobayashi, K. Matsumoto, and Y. Morishita. 2001, FR167653 attenuates ischemia and reperfusion injury of the rat lung with suppressing p38 MAPK. J. Heart Lung Transplant. 20:568.
54. Barone, F. C., E. A. Irving, A. M. Ray, J. C. Lee, S. Kassis, S. Kumar, A. M. Badger, R. F. White, M. J. McVey, J. J. Legos, et al. 2001. SB239063, a second-generation p38 MAPK inhibitor, reduced brain injury and neurological deficits in cerebral focal ischemia. J. Pharmacol. Exp. Ther. 296:312.
55. Raingeaud, J., A. J. Whitmarsh, T. Barrett, B. Derijard, and R. J. Davis. 1996. MKK-3 and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol. Cell. Biol. 16:1247.
56. She, Q., N. Chen, and Z. Dong. 2000. ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UV radiation. J. Biol. Chem. 275:20444.
57. Wang, X. Z., and D. Ron. 1996. Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD 153) by p38 MAP kinase. Science 272:1347.
58. Han, J., Y. Jiang, Z. Li, V. V. Kravchenko, and R. J. Ulevtich. 1997. Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature 386:296.
59. Nick, J. A., N. J. Avdi, S. K. Young, L. A. Lehman, P. P. McDonald, S. C. Frasch, M. A. Billstrom, P. M. Henson, G. L. Johnson, and G. S. Worthen. 1999. Selective activation and functional significance of p38α mitogen-activated protein kinase in lipopolysaccharide-stimulated neutrophils. J. Clin. Invest. 103:851.
60. Carter, A. B., M. M. Monick, and G. W. Hunninghake. 1999. Both Erk and p38 kinase are necessary for cytokine gene transcription. Am. J. Respir. Cell Mol. Biol. 20:751.
61. Pouliot, M., J. Baillargeon, J. C. Lee, L. G. Cleland, and M. J. James. 1997. Inhibition of prostaglandin endoperoxide synthase-2 expression in stimulated human monocytes by inhibitors of p38 mitogen-activated protein kinase. J. Immunol. 158:4930.
62. Baeuerle, P. A., and T. Henkel. 1994. Function and activation of NF-κB in the immune system. Annu. Rev. Immunol. 12:141.
63. Berghe, W. V., S. Plaisance, E. Boone, K. D. Bosscher, M. L. Schmitz, W. Fiers, and G. Haegeman. 1998. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-KB p65: Transactivation mediated by tumor necrosis factor. J. Biol. Chem. 273:3285.
64. Beyaert, R., A. Cuenda, W. Vanden Berghe, S. Plaisance, J. C. Lee, G. Haegeman, P. Cohen, and W. Fiers. 1996. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumour necrosis factor. EMBO J. 15:1914.
65. Prichett, W., A. Hand, J. Sheilds. and D. Dunningyon. 1995. Mechanism of action of bicyclic imidazoles defines a translational regulatory pathway for tumor necrosis factor α. J. Inflammation 45:97.
66. Waskiewicz, A. J., A. Flynn, C. G. Proud, and J. A. Cooper. 1997. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J. 16:1909.
67. Brook, M., G. Sully, A. R. Clark, and J. Saklatvala. 2000. Regulation of TNF-α mRNA stability by the MAP kinase p38 signaling cascade. FEBS Lett. 483:57.
68. Winzen, R., M. Kracht, B. Ritter, A. Wilhelm, C. A. Chen, A. Shyu, M. Muller, M. Gaestel, K. Resch, and H. Holtmann. 1999. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J. 18:4969.
69. Kotlyarov, A., A. Neininger, C. Schubert, R. Eckert, C. Birchmeier, H. D. Volk, and M. Gaestel. 1999. MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis. Nat. Cell Biol. 1:94.
70. Stokoe, D., D. Campbell, S. Nakielny, H. Hadaka, S. Leevers, C. Marshall, and P. Cohen. 1992. MAPKAP kinase-2: a novel protein kinase activated by mitogen-activated protein kinase. EMBO J. 11:3985.
71. Sithanandam, G. 1996. 3pK, a new mitogen-activated protein kinase-activated protein kinase located in the small cell lung cancer tumor suppressor gene region. Mol. Cell. Biol. 16:868.
72. New, L., Y. Jong, M. Zhao, K. Liu, W. Zhu, L. Flood, Y. Kato, G. Parry, and J. Han. 1998. PRAK, a novel protein kinase regulated by the p38 MAP kinase. EMBO J. 17:3372.
73. Deak, M., A. Clifton, J. Lucocq, and D. Alessi. 1998. Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J. 17:4426.
74. -/- neutrophils in Zigmond chambers containing FMLP gradients. J. Immunol. 167:3953.
75. Huang, C., L. Zhan, Y. Ai, and J. Jonstra. 1997. LSPI is the major substrate for mitogen-activated protein kinase activated protein kinase 2 in human neutrophils. J. Biol. Chem. 272:17.
76. Lei, B. Z., Z. Zhang, J. Qing, Q. Yong-Wen, P. Gang, B. Z. Cao, and X. Y. Li. 2002. OxLDL upregulates CXCR2 expression in monocytes via scavenger receptors and activation of p38 mitogen-activated protein kinase. Cardiovasc. Res. 53:524.
77. Zhang, C., R. A. Baumgartner, K. Yamada, and M. A. Beaven. 1997. Mitogen-activated protein (MAP) kinase regulates production of tumor necrosis factor-a and release of arachidonic acid in mast cells. Indications of communication between p38 and p42 MAP kinases. J. Biol. Chem. 272:13397.